Skip to main content
Finch's C. difficile infection drug granted breakthrough status
2/11/2019

The FDA has assigned breakthrough therapy status to Finch Therapeutics' oral full-spectrum microbiota product, which is in a midstage study for the treatment of patients with recurrent Clostridium difficile infection.

Full Story: